A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors

Bristol-Myers Squibb (BMS)

Status and phase

Completed

Phase 1

Conditions

Advanced Cancer

Treatments

Biological: Nivolumab

Drug: BMS-986205

Study type

Interventional

Funder types

Industry

Identifiers

NCT03192943

CA017-048

Details and patient eligibility

About

The purpose of this study is to assess the safety and tolerability for the combination therapy of BMS-986205 and Nivolumab in patients with advanced tumors

Enrollment

11 patients

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Participants must have histologic or cytological confirmation of a malignancy that is advanced (metastatic and/or unresectable) with measureable disease per Response Evaluation Criteria In Solid Tumors (RECIST v1.1)
Participants must have received, and then progressed or been intolerant to standard treatment regimen in the advanced or metastatic setting
Eastern Cooperative Oncology Group performance status of ≤ 1

Exclusion criteria

Participants with known or suspected CNS metastases, untreated CNS metastases, or with the CNS as the only site of disease are excluded
History of congenital or autoimmune hemolytic disorders
History or presence of hypersensitivity or idiosyncratic reaction to methylene blue

Other protocol defined inclusion/exclusion criteria could apply